Introduction: MI is the leading cause of adult death in the United States (US). It is the predominant cause and responsible for more than 80% of CVD deaths in India. Objective: The objective of this study is to compare the effectiveness, adverse effects, mortality and safety profile of two anti-coagulants (LMWH & UFH) in the patients of acute coronary syndrome (NSTEMI). Methodology: A prospective observation study conducted on 70 adult patients at Durgabhai Deshmukh Hospital and Research Centre, Hyderabad on patients admitted for elective surgery for a period of six months. Results: Among 70 patients 56(80%) are males and 14 (20%) are females. Among all age groups major numbers of NSTEMI patients are seen in 51-60 years (30%). Among all patients 56 out of 70 patients i.e., 80% are with chest pain as chief complaint, 19 patients i.e., 27% are with sweating as chief complaint, 21 patients are with shortness of breath (SOB) as chief complaint i.e., 30% and 9 patients are with palpitations as chief complaint i.e., 13%. Among all patients 8 out of 70 patients suffered gastric bleeding i.e., 11.4% and 1 out of 70 patients suffered from intracranial bleeding i.e., 1.42%.Among all patients 9 patients out of 70 suffered with heart failure i.e., 12.85%, 22 patients out of 70 suffered with tachyarrhythmia i.e., 31.4%, and 13 patients suffered local bleeding i.e., 18.57%. Conclusion: From the study it is concluded that, patients with NSTEMI are given both the regimens i.e., low molecular weight heparin and un fractionated heparin and found that 27% more risk is observed in regimen 2 i.e., un fractionated heparin until the limited follow up that has done.
Cite this article:
Ruheena Yasmeen, N. Krishna Reddy, Marina. G. D’ Souza, B. Swathi, Anas Abdul Waheed, Katakam Chinmayee, J. Vineeth Reddy. Study of Anticoagulants low molecular weight heparin and Unfractionated heparin in the management of Non-St elevation Myocardial Infarction. Research J. Pharm. and Tech. 2020; 13(7): 3151-3155. doi: 10.5958/0974-360X.2020.00557.0
1. Marc Cohen, M.D., Christine Demers, M.D., Enrique P. Gurfinkel, M.D., Alexander G.G. Turpie, M.D., Gregg J. Fromell, M.D., Shaun Goodman, M.D., Anatoly Langer, A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease, 1997 Aug: 337.447-452.
2. Marc Cohen MD, D. White MB, DSce, W. Van, Mieghem MD - Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The acute -2 study, 2002 Sep, 144(3): 470-477.
3. Navarsee E.P, De luca G, Castriota F, Kozinski M, Andreotti F, Buffon A, De Servi S, low molecular –weight heparins vs unfractionated heparin in the setting of percutaneous coronary intervention for NSTEMI: a meta analysis, 2011 oct 10, 1902-1915.
4. Eugene Braunwald, Elliott Antman M, John Beasley W, Robert Califf W, Melvin D Cheitlin, Judith S Hochman, Robert H Jones, Dean Kereiakes, Joel Kupersmith, Thomas N Levin, Carl J Pepine, John W Schaeffer, Earl E Smith III, David E Steward, Pierre Theroux, Raymond J Gibbons, Elliott M Antman, Joseph S Alpert, David P Faxon, Valentin Fuster, Gabriel Gregoratos, Loren F Hiratzka, Alice K Jacobs and Sidney C Smith Jr-lmwhvsufh in management of patients with unstable angina and non–ST-segment elevation myocardial infarction: 2002oct 7;2336-2337.
5. Gilles Montalescot, Claire Bal-dit-Sollier, Daniela Chibedi, Jean-Philippe Collet, Thierry Soulat, Miles Dalby, R.émi Choussat, Ariel Cohen, Michel Slama, Phillipe Gabriel Steg, Jean-Luc Dubois-Randé, Jean-Philippe Metzger, François Tarragano, Jean L Guermonprez, Ludovic Drouet. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non–ST-segment elevation acute myocardial infarction: 2003, 91(8); 925–930.
6. Mushtaq Ahmed, Mohammad Tariq, Lubna Noor, Shahab Ud Din, Mohammad Hafizullah–Comparison of enoxaparin and dalteparin with ufh in NSTEMI: 2011 April, 23(3); 61-65.
7. Wayangankar SA, Roe MT, Chen AY, Gupta RS, Giugliano RP, Newby LK, de Lemos JA, Alexander KP, Sanborn TA, Saucedo JF-Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy:2016 Jul-Aug;68(4):464-72
8. Chiara Melloni, W. Schuyler Jones, Jeffrey B. Washam, Victor Hasselblad, Stephanie B. Mayer, Sharif Halim, Sumeet Subherwal, Karen Alexander, David F. Kong, Brooke L. Heidenfelder, R. Julian Irvine, Liz Wing, Rowena J. Dolor-Antiplatelet and anticoagulant treatments for unstable angina/non-ST elevation myocardial infarction; 2013sep; 13(14); 172
9. Erlinge D, Omerovic E, Fröbert O, Linder R, Danielewicz M, Hamid M, Swahn E, Henareh L, Wagner H, Hårdhammar P, Sjögren I, Stewart J, Grimfjärd P, Jensen J, Aasa M, Robertsson L, Lundin A, Tödt T, Ioanes D, Råmunddal T, Kellerth T, Zagozdzon L, Götberg M -Bivalirudin versus Heparin Monotherapy in Myocardial Infarction;2017 Sep 21;377(12):1132-1142.
10. Moscucc M, Fox K.A.A. Christopher P. Cannon W. Klein José López-Sendón G. Montalescot K. White R.J. Goldberg- Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE):2003 Oct 1;1815–1823,
11. Montalescot G, Collet JP, Tanguy M., Ankri. A, Payot. L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas. D-Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin: 2004 July; 3